Morgan Stanley Ayala Pharmaceuticals, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.38 - $0.71 $912 - $1,704	-2,400 Reduced 14.7%	13,931 $5,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.97 $13,096 - $31,462	15,971 Added 4436.39%	16,331 $16,000
Q2 2022 Oct 27, 2022	SELL	$0.99 - $4.15 $1,699 - $7,125	-1,717 Reduced 82.67%	360 $0
Q2 2022 Aug 15, 2022	SELL	$0.99 - $4.15 $1,699 - $7,125	-1,717 Reduced 82.67%	360 $0
Q1 2022 Oct 27, 2022	BUY	$3.5 - $9.11 $6,009 - $15,641	1,717 Added 476.94%	2,077 $8,000

Q1 2022 May 13, 2022	BUY	$3.5 - $9.11 $1,330 - $3,461	380 Added 22.39%	2,077 $8,000
Q4 2021 Feb 14, 2022	BUY	$8.32 - $12.45 $11,123 - $16,645	1,337 Added 371.39%	1,697 $14,000
Q3 2021 Nov 15, 2021	BUY	$8.13 - $14.09 $2,926 - $5,072	360 New	360 $4,000

Ticker AYLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,833,300
Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinic...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.